Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer (EA2165)
Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer (EA2165)
Trial Category:
Gastrointestinal
Phase
II
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
